Core Insights - Invivyd (NASDAQ: IVVD) is gaining attention due to its monoclonal antibody candidate as an alternative to traditional COVID-19 vaccines, with shares rising 73% to $0.97 after closing at $0.56 [1][3] - The company's proprietary INVYMAB platform utilizes viral surveillance, predictive modeling, and advanced antibody engineering to develop next-generation therapies, starting with SARS-CoV-2 [3] - A recent $58 million financing round led by RA Capital and Janus Henderson has bolstered investor confidence in Invivyd's long-term development [4] Market Context - The stock price surge coincides with reports of a potential U.S. policy shift regarding reduced support for traditional COVID-19 vaccines, increasing interest in alternatives like Invivyd's approach [5] - Previous significant stock movement occurred in February, where shares spiked nearly 193% following positive safety and pharmacokinetic data [5]